Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

Gut

Volumn 51, Issue 1, 2002, Pages 30-36

  Yacyshyn, Bruce R ^a   Chey, W Y ^b   Goff, J ^c   Salzberg, B ^d   Baerg, R ^e   Buchman, A L ^f   Tami, J ^g   Yu, R ^g   Gibiansky, E ^h   Shanahan, W R ^g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ROCHESTER   (United States)

^c Western States Clinical Research   (United States)

^d Atlanta Gastroenterology Associates   (United States)

^e Tacoma Digestive Disease Center   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g ISIS PHARMACEUTICALS   (United States)

^h ICON Development Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; INTERCELLULAR ADHESION MOLECULE 1; PREDNISONE; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PREDNISONE; REMISSION INDUCTION; SEX FACTORS; THIONUCLEOTIDES;

EID: 0036288638     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.51.1.30     Document Type: Article

References (44)

1. Clinical features and complications of Crohn's disease
2. Traffic signals for lymphocyte recirculation and leukocyte migration: The multistep paradigm
3. Beta 2 integrin/ICAM expression in Crohn's disease
4. Induction by IL-1 and interferon: Tissue distribution biochemistry, and function of a natural adherence molecule (ICAM-1)
5. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1
6. ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM
7. Regulation of adhesion molecule expression by human synovial microvascular endothelial cells in vitro
8. The role of tumor necrosis factor in health and disease
9. Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease
10. Up-regulation of E-selectin and ICAM-1 differs between Crohn's disease and ulcerative colitis
11. Expression of lymphocyte-endothelial receptor-ligand pairs, α4 β7/MAdCAM-1 and OX40/OX 40 ligand in the colon and jejunum of patients with inflammatory bowel disease
12. Regulation of ICAM-1 mediated fibroblast-T cell reciprocal interaction: Implications for modulation of gut inflammation
13. Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns
14. T cell function and migration: Two sides of the same coin
15. Increased expression of costimulatory molecules on peripheral blood monocytes in patients with Crohn's disease
16. Comparative studies of the colonic in situ expression of ICAM-1, -2, and -3, beta 2 integrins (LFA-1, Mac-1, and p150, 95), and PECAM-1 in ulcerative colitis and Crohn's disease
17. A phase I/II open label study of the safety and efficacy of an anti-intercellular adhesion molecule 1 monoclonal antibody in early rheumatoid arthritis
18. Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis
19. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody
20. Effects of administration of a single dose of a humanized monoclonal antibody to CD1 1a on the immunobiology and clinical activity of psoriasis
21. Inhibition of endothelial cell leukocyte adhesion molecule expression with antisense oligonucleotides
22. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
23. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1
24. Properties of cloned and expressed human RNase H1
25. Enhanced metastatic ability of TNF-α treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (CD54) antisense oligonucleotides
26. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides inkeratinocytes
27. Blocking of heart allograft rejection by ICAM-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities
28. The role of ICAM-1 in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice
29. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice
30. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligonucleotide (ISIS 2302)
31. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex
32. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action
33. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
34. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
35. Properties of ISIS 2302 in humans
36. Methotrexate for the treatment of Crohn's disease
37. A form of circulating ICAM-1 in human serum
38. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis
39. Quantitation of phosphorothioate oligonucleotides in human plasma
40. Multiple dose pharmacokinetics of a long half-life drug: Contributions of mathematical modeling
41. Inferring systemic exposure from a pharmacokinetic screen: Model-free and model-based approaches
42. PCNONLIN and NONLIN84: Software for the statistical analysis of nonlinear models
43. Estradiol enhances leukocyte binding to TNF-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule type 1
44. A pilot study of ISIS 2302, an antisense oligodeoxynucleotide, in patients with active rheumatoid arthritis